Literature DB >> 3348387

Parathyroid hormone-independent regulation of 1,25(OH)2D in response to inhibition of bone resorption.

J P Bonjour1, U Trechsel, C M Taylor, H Fleisch.   

Abstract

Both plasma level of 1,25-dihydroxyvitamin D [1,25(OH)2D] and intestinal Ca absorption increase after biphosphonate-induced inhibition of bone resorption. Parathyroid hormone (PTH) has been considered a key mediating element of this homeostatic response. In the present work, the role of PTH was assessed by studying the influence of 1-hydroxypentane-1,1-bisphosphonate (HPeBP) on vitamin D and Ca metabolism in both intact and thyroparathyroidectomized (TPTX) rats. In intact rats, HPeBP given at 0.1 mg P/kg body wt sc for 10 days strongly inhibited bone resorption without affecting bone formation. This effect was associated with a marked stimulation of intestinal Ca absorption and Ca balance. In this condition, HPeBP caused a marked rise in plasma 1.25(OH)2D without affecting the level of 25-hydroxyvitamin D. In TPTX rats, HPeBP given at same dose also inhibited bone resorption and enhanced plasma 1,25(OH)2D, intestinal Ca absorption and Ca balance. In summary, this study shows that bisphosphonates such as HPeBP with prevailing inhibitory activity on bone resorption induce a marked stimulation of both 1,25(OH)2D production and intestinal Ca absorption. This homeostatic response is not attenuated after PTH removal. Thus, as previously shown for the response to low Ca diet, PTH does not appear to be an essential mediating factor for stimulating 1,25(OH)2D production in response to an increase in bone mineral retention.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3348387     DOI: 10.1152/ajpendo.1988.254.3.E260

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  7 in total

1.  Prolonged, symptomatic hypocalcemia with pamidronate administration and subclinical hypoparathyroidism.

Authors:  A Mishra; L Wong; J Jonklaas
Journal:  Endocrine       Date:  2001-03       Impact factor: 3.633

Review 2.  Clodronate in hypercalcemia of malignancy.

Authors:  J P Bonjour; R Rizzoli
Journal:  Calcif Tissue Int       Date:  1990       Impact factor: 4.333

3.  The bisphosphonate ibandronate, given daily as well as discontinuously, decreases bone resorption and increases calcium retention as assessed by 45Ca kinetics in the intact rat.

Authors:  H Fleisch
Journal:  Osteoporos Int       Date:  1996       Impact factor: 4.507

4.  Inhibition of bone mineral loss during lactation by Cl2MBP.

Authors:  R Brommage; D C Baxter
Journal:  Calcif Tissue Int       Date:  1990-09       Impact factor: 4.333

Review 5.  Hypercalcaemia of malignancy.

Authors:  P J Kelly; J A Eisman
Journal:  Cancer Metastasis Rev       Date:  1989-06       Impact factor: 9.264

6.  Hypercalcemia associated with dysregulation of 1,25-dihydroxyvitamin D in arthritis.

Authors:  J L Shaker; G E Auger; P P Wendt; J W Findling
Journal:  J Endocrinol Invest       Date:  1992-11       Impact factor: 4.256

7.  Skeletal and mineral metabolic effects of risedronate in a rat model of high-turnover renal osteodystrophy.

Authors:  Hiroaki Ishida; Hirotaka Komaba; Naoto Hamano; Hideyuki Yamato; Kaichiro Sawada; Takehiko Wada; Michio Nakamura; Masafumi Fukagawa
Journal:  J Bone Miner Metab       Date:  2020-03-05       Impact factor: 2.626

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.